Hays Advisory Lowers stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Hays Advisory reduced its stake in United Therapeutics Corporation by 14.05% during the most recent quarter end. The investment management company now holds a total of 42,203 shares of United Therapeutics Corporation which is valued at $4,846,170 after selling 6,897 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.United Therapeutics Corporation makes up approximately 0.74% of Hays Advisory’s portfolio.

Other Hedge Funds, Including , Nordea Investment Management Ab boosted its stake in UTHR in the latest quarter, The investment management firm added 190 additional shares and now holds a total of 1,208 shares of United Therapeutics Corporation which is valued at $138,715. Fox Run Management L.l.c. sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 4,200 shares of UTHR which is valued $482,286. Eqis Capital Management added UTHR to its portfolio by purchasing 2,394 company shares during the most recent quarter which is valued at $265,399. United Therapeutics Corporation makes up approx 0.02% of Eqis Capital Management’s portfolio.

United Therapeutics Corporation opened for trading at $112 and hit $115.12 on the upside on Wednesday, eventually ending the session at $114.83, with a gain of 3.57% or 3.96 points. The heightened volatility saw the trading volume jump to 6,76,726 shares. Company has a market cap of $5,124 M.

On the company’s financial health, United Therapeutics Corporation reported $3.02 EPS for the quarter, missing the analyst consensus estimate by $ -0.32 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.34. The company had revenue of $369.00 million for the quarter, compared to analysts expectations of $397.24 million. The company’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .United Therapeutics Corporation was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 29, 2016.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.